In a nutshell
This study examined the relationship between the time taken to start adjuvant chemotherapy and survival. The authors determined that a delay in adjuvant chemotherapy was associated with reduced survival.
Some background
Adjuvant chemotherapy is additional chemotherapy given after surgery. It is routinely used in women who are at risk of cancer returning after surgery. It reduces the risk of cancer spreading to other parts of the body and has been associated with improved survival. Previous studies describe a 12-week or less period to starting adjuvant therapy after surgery. The time from breast cancer diagnosis to starting adjuvant therapy has increased over the last 10 years. The best time to start adjuvant therapy after surgery is not known.
Methods & findings
This study examined the timing of adjuvant chemotherapy following surgery in breast cancer. This analysis included 14 studies including 18 study populations. Each study reported the time to adjuvant chemotherapy (TTAC). The relationship between TTAC and survival was also examined.
There was a relationship between the TTAC and survival in women who received adjuvant therapy for breast cancer. A 4-week increase in TTAC was associated with a 4-8% increase in risk of death.
The bottom line
This study suggests that a delay in adjuvant therapy following surgery makes it less effective and decreases chances of survival.
The fine print
This study is based entirely on the results of other observational studies. A specific study that examines the impact of delaying adjuvant therapy is required. The effect of the delay is dependent on each patient's individual circumstances.
What’s next?
Speak to your doctor if you are concerned about delays in commencing adjuvant therapy.
Published By :
Breast Cancer Research and Treatment
Date :
Sep 08, 2016
